
usd feb pm et
summari compani one largest world-wide provid integr dialysi servic
patient suffer chronic kidney failur
price-to-earnings oper ep
risk assess reflect stabl demand dialysi
servic driven rise senior popul
off-set depend third-parti payment
includ medicar medicaid
may ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lower target
base enterpris valu
ebitda ratio
equal dva averag ep
vs lower estim
lower ep
initi ep sale
increas billion
year-over-year revenu per treatment
per treatment opinion driven
less favor patient mix expect
significantli slow open
treatment center slow growth
end-stag renal diseas industri
increas number patient
treat home reincarn
california bill sb call ab
threaten neg impact dva revenu
previou california
governor veto bill sb new
governor may feel way /kevin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview davita inc lead provid dialysi relat servic patient
suffer chronic kidney failur also known end-stag renal diseas esrd decemb
compani oper provid administr servic network outpati
dialysi center design specif outpati hemodialysi
result growth acquisit occasion becom highli leverag
opinion acquir center gambro acquisit well independ
center compani acquir center open new center sold six close
septemb acquir dsi renal ad facil led divestitur mani
dsi portfolio novemb complet merger privately-held healthcar partner
physician practic network billion payabl billion cash million share
decemb enter agreement sell davita medic group collabor
hold subsidiari billion cash sale expect close
improv compani financi flexibl
hemodialysi use artifici kidney call dialyz remov certain toxin fluid salt
patient blood togeth machin control extern blood flow monitor certain vital sign
patient periton dialysi use patient periton abdomin caviti elimin fluid
market profil esrd state advanc renal impair irrevers requir routin
dialysi treatment kidney transplant sustain life treatment option esrd includ
hemodialysi periton dialysi kidney transplant growth procedur driven
age popul increas incid rate diseas caus kidney failur
diabet hypertens lower mortal rate dialysi patient growth rate minor
popul higher-than-averag incid rate esrd assum dialysi market
 continu grow mid-singl digit rang next sever year age
popul keep long-term growth mid-singl digit rang
legal/regulatori issu govern medicar medicaid remain primari
payor care esrd dialysi patient account roughli two-third dialysi revenu
medicar account major govern revenu balanc deriv
commerci payor esrd payment rate dialysi establish congress medicar composit
rate set center medicar medicaid servic includ payment dialysi
treatment suppli use treatment specifi laboratori test certain pharmaceut
provid paid separ servic pharmaceut includ erythropoietin epo
vitamin analog iron supplement gener averag cost servic pharmaceut
plu small margin base price set medicar medicar payment rate suffici
cover averag cost provid dialysi treatment
cover treatment medicar pay amount set medicar system patient
respons remain case secondari payor cover part
financi trend averag revenu per treatment
level volatil recent year due fluctuat patient mix
commerci govern insur patient go forward expect revenu growth mid-
upper singl digit ep growth low-doubl digit expand oper
domest intern address medicar reimburs cut may berkshir
hathaway took stake agre standstil agreement acquir
stake decemb berkshir stake septemb
complet stock split rais number share outstand million
offic intern
presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
individu mandat passag
tax cut job act decemb
see develop neg health
care servic servic fewer custom
like enrol insur plan start
fewer patient insur uncompens
care rate could rise hospit health
care facil lead lower profit
lower demand supplement health care
pharmaci benefit manag pbm
hurt recent lower level drug price
inflat increas pressur third
parti payer partial allevi high
util pbm merg insur
off-set pressur notabl health
acquir aetna aet ci
major pbm integr
major insur potenti threat
power entiti amazon
recent enter health care
 health servic index
increas vs decreas
fundament outlook health care
servic sub-industri next month
neutral sub-industri perform well
last quarter strength
 economi result lower
number uninsur individu better health
care coverag higher employ strong
economi also led shortag labor
health care servic long run
think health care servic
continu benefit modestli age
popul increas focu
prevent care offset posit
trend continu pressur reduc
cost health care system
wave support democrat parti
novemb mid-term elect
result democrat take control
hous repres increas
medicaid coverag sever state
increas coverag boon health care
servic mani democrat appear run
medicar platform
would like lower averag rate
anoth headlin risk potenti repeal
afford act judg
texa rule unconstitut
oppon appeal decis
current expect upheld upon
appeal although decis could take
coupl year reach
repeal expect impact would neg
health care servic less
health care facil benefit
increas insur coverag
past sever year also
democrat control hous
repres expect
seriou attempt republican repeal
republican success elimin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
enterpris valu ev ebitda ratio in-lin peer
ep vs higher estim lower
ep ep sale increas
billion total dialysi treatment grew year-over-year
revenu per treatment slightli well adjust medicar
bad debt recoveri manag note two regulatori overhang
could materi california ballot initi implement profit cap
dialysi provid propos bill sb would limit econom
benefit charit premium assist adjust oper margin
declin wage price pressur
et cfra maintain hold opinion share inc
keep target price appli ev/ebitda
multipl estim slight discount peer averag
reflect slow revenu growth outlook regulatori headwind rais
ep estim trim
report oper ep vs consensu
revenu increas aid increas number treatment
per day growth revenu per treatment see oper margin
expand driven pend sale davita medic group
segment expect declin sale due segment sale
growth modest increas volum revenu per treatment
rais target price appli
ev/ebitda multipl estim line peer
balanc reimburs rate pressur expect benefit
sale medic group segment increas ep estim
set report oper ep
vs line consensu sale increas aid
growth treatment per day expect experi margin pressur
driven increas labor cost flat reimburs rate /keith
analyst research note compani news
pm et cfra maintain hold opinion share davita inc
lower target base enterpris
valu ebitda ratio equal dva
averag ep vs lower estim
lower ep initi ep
sale increas billion organ treatment growth
increas year-over-year revenu per treatment decreas
sequenti lower revenu per treatment opinion driven less
favor patient mix expect significantli slow
open treatment center slow growth end-stag renal
diseas industri increas number patient treat
home reincarn california bill sb call ab
threaten neg impact dva revenu
previou california governor veto bill sb new governor may
feel way /kevin huang cfa
lower twelve-month target base total
enterpris valu ev next-twelve-month ntm ebitda ratio
five-year averag lower ev ntm ebitda ratio
see fewer long-term growth opportun also lower
ep dissip previou regulatori
overhang expect signific catalyst near futur
expect continu spend fend unfavor regulatori propos
think valuat could posit impact strateg
smart capit alloc decis manag especi
divestitur davita medic group dmg busi complet expect
/kevin huang cfa
maintain target base total enterpris
valu ebitda ratio in-lin peer ep
vs lower estim lower ep
ep sale increas
billion total dialysi treatment per-day basi grew
year-over-year sinc earn call two regulatori overhang bill
prop note dissip howev lower
high end oper incom guidanc compani increas
spend relat advocaci chang execut retir polici
anticip increas baselin spend million per year
gener advocaci continu work optum close sale
davita medic group dmg busi end think could
substanti increas share repurchas activ upon close dmg
et cfra keep hold opinion share inc
share trade midmorn news proposit
vote californian proposit look implement profit cap
dialysi provid failur ballot initi posit
given report tomorrow novemb await
earn updat estim target price maintain hold
et cfra maintain hold opinion share inc
dva share fell midday approv dialysi
legisl sb california assembl bill becom law
still must make past state senat governor
legisl sb pass would limit econom benefit
charit premium assist put cap commerci dialysi payment
medicar rate typic lower /kevin huang cfa
lift target base total
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
